Drug Profile
TPI 287
Alternative Names: ARC-100; NBT 287; TPI-287Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Tapestry Pharmaceuticals
- Developer Archer Biosciences; Cortice Biosciences; H. Lee Moffitt Cancer Center and Research Institute; Tapestry Pharmaceuticals; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; Van Andel Research Institute
- Class Antidementias; Antineoplastics; Small molecules; Taxanes
- Mechanism of Action Microtubule protein modulators; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Glioblastoma
- Phase I/II Malignant melanoma
- No development reported Alzheimer's disease; Cancer; Corticobasal degeneration; Medulloblastoma; Neuroblastoma; Non-small cell lung cancer; Progressive supranuclear palsy
- Discontinued Pancreatic cancer; Prostate cancer
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (IV, Infusion)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Corticobasal-degeneration in USA (IV, Infusion)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Metastatic disease) in USA (IV, Infusion)